Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT05588843Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2022
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of eclitasertib in ulcerative colitis (UC) (4 arms), sponsored by Sanofi. Primary endpoint: Clinical Remission by modified Mayo Score at 12 weeks. Started Nov 2022; status: active, not recruiting.
02
Drugs
eclitasertib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05588843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588843.